title: Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.
abstract: The blood-brain barrier (BBB) contributes to brain homeostasis by protecting the brain from potentially harmful endogenous and exogenous substances. BBB active drug efflux transporters of the ATP-binding cassette (ABC) gene family are increasingly recognized as important determinants of drug distribution to, and elimination from, the CNS. The ABC efflux transporter P-glycoprotein (Pgp) has been demonstrated as a key element of the BBB that can actively transport a huge variety of lipophilic drugs out of the brain capillary endothelial cells that form the BBB. In addition to Pgp, other ABC efflux transporters such as members of the multidrug resistance protein (MRP) family and breast cancer resistance protein (BCRP) seem to contribute to BBB function. Consequences of ABC efflux transporters in the BBB include minimizing or avoiding neurotoxic adverse effects of drugs that otherwise would penetrate into the brain. However, ABC efflux transporters may also limit the central distribution of drugs that are beneficial to treat CNS diseases. Furthermore, neurological disorders such as epilepsy may be associated with overexpression of ABC efflux transporters at the BBB, resulting in pharmacoresistance to therapeutic medication. Therefore, modulation of ABC efflux transporters at the BBB forms a novel strategy to enhance the penetration of drugs into the brain and may yield new therapeutic options for drug-resistant CNS diseases.
authors.affiliation: Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Hannover D-30559, Germany. wolfgang.loescher@tiho-hannover.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Löscher
authors.forename: Heidrun
authors.initials: H
authors.lastname: Potschka
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000378:metabolism*; D000818:Animals; D001812:Blood-Brain Barrier / Q000502:physiology*; D001921:Brain / Q000378:metabolism; D004351:Drug Resistance; D006801:Humans
chemical_list: D018528:ATP-Binding Cassette Transporters
references.citation: Biochim Biophys Acta. 1999 Dec 6;1461(2):347-57
references.pmid: 10581366
references.citation: Novartis Found Symp. 2002;243:19-31; discussion 31-7, 180-5
references.pmid: 11990777
references.citation: J Histochem Cytochem. 1989 Feb;37(2):159-64
references.pmid: 2463300
references.citation: Brain. 2002 Jan;125(Pt 1):22-31
references.pmid: 11834590
references.citation: Trends Pharmacol Sci. 2002 Mar;23(3):113-8
references.pmid: 11879677
references.citation: Int J Clin Pharmacol Ther. 1998 Jan;36(1):50-4
references.pmid: 9476149
references.citation: Top HIV Med. 2003 Jul-Aug;11(4):136-9
references.pmid: 12876331
references.citation: Adv Drug Deliv Rev. 2002 Mar 31;54(3):315-28
references.pmid: 11922950
references.citation: Br J Hosp Med. 1991 Jan;45(1):32-4
references.pmid: 2009437
references.citation: Epilepsy Behav. 2003 Dec;4 Suppl 4:S26-30
references.pmid: 14654425
references.citation: Curr Pharm Des. 2004;10(12):1313-24
references.pmid: 15134483
references.citation: Proc Natl Acad Sci U S A. 1989 Jan;86(2):695-8
references.pmid: 2563168
references.citation: Curr Drug Targets. 2003 May;4(4):297-304
references.pmid: 12699350
references.citation: Mol Microbiol. 2002 Jun;44(5):1123-30
references.pmid: 12068801
references.citation: Neuroscience. 2004;123(3):751-9
references.pmid: 14706787
references.citation: Biochem Pharmacol. 2004 Jan 15;67(2):269-76
references.pmid: 14698039
references.citation: J Pharmacol Exp Ther. 2003 Jul;306(1):124-31
references.pmid: 12663688
references.citation: Psychiatr Clin North Am. 1998 Jun;21(2):293-307
references.pmid: 9670227
references.citation: Pharmacol Rev. 2001 Dec;53(4):569-96
references.pmid: 11734619
references.citation: Mol Pharmacol. 2000 Dec;58(6):1357-67
references.pmid: 11093774
references.citation: Curr Opin Neurol. 2003 Apr;16(2):197-201
references.pmid: 12644749
references.citation: J Pharmacol Exp Ther. 2002 Aug;302(2):407-15
references.pmid: 12130697
references.citation: Leuk Lymphoma. 2002 Jun;43(6):1221-8
references.pmid: 12152989
references.citation: Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):179-194
references.pmid: 10837715
references.citation: Anesthesiology. 2000 May;92(5):1392-9
references.pmid: 10781286
references.citation: Pharmacology. 2004 Apr;70(4):169-76
references.pmid: 15001817
references.citation: Neuropsychopharmacology. 2000 Apr;22(4):380-7
references.pmid: 10700657
references.citation: Adv Drug Deliv Rev. 2003 Jan 21;55(1):83-105
references.pmid: 12535575
references.citation: Neuroreport. 1999 Nov 8;10(16):3437-41
references.pmid: 10599858
references.citation: Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2470-5
references.pmid: 14983033
references.citation: Curr Drug Metab. 2004 Feb;5(1):95-108
references.pmid: 14965253
references.citation: Pharm Biotechnol. 1999;12:353-86
references.pmid: 10742982
references.citation: Br J Pharmacol. 1999 Oct;128(3):563-8
references.pmid: 10516633
references.citation: Novartis Found Symp. 2002;243:38-47; discussion 47-53, 180-5
references.pmid: 11990780
references.citation: Novartis Found Symp. 2002;243:149-59; discussion 159-66, 180-5
references.pmid: 11990774
references.citation: Psychiatr Clin North Am. 1996 Jun;19(2):179-200
references.pmid: 8827185
references.citation: N Engl J Med. 2003 Apr 10;348(15):1442-8
references.pmid: 12686700
references.citation: Epilepsia. 2003 Nov;44(11):1388-96
references.pmid: 14636345
references.citation: Epilepsia. 2004 May;45(5):441-51
references.pmid: 15101825
references.citation: Nat Med. 2004 Jul;10(7):685-92
references.pmid: 15229516
references.citation: Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3900-5
references.pmid: 10097135
references.citation: Int J Clin Pharmacol Ther. 2000 Mar;38(3):111-21
references.pmid: 10739114
references.citation: Vascul Pharmacol. 2002 Jun;38(6):339-48
references.pmid: 12529928
references.citation: Epilepsia. 2003 Dec;44(12):1479-86
references.pmid: 14636316
references.citation: Cancer Control. 2003 Mar-Apr;10(2):159-65
references.pmid: 12712010
references.citation: Drug Metab Dispos. 2003 Nov;31(11):1337-45
references.pmid: 14570765
references.citation: Cancer Res. 2004 May 1;64(9):3296-301
references.pmid: 15126373
references.citation: Drugs Today (Barc). 2004 Jan;40(1):5-22
references.pmid: 14988766
references.citation: Oncogene. 2003 Oct 20;22(47):7340-58
references.pmid: 14576842
references.citation: Neuroreport. 2002 Nov 15;13(16):2059-63
references.pmid: 12438926
references.citation: J Clin Invest. 1998 Jan 15;101(2):289-94
references.pmid: 9435299
references.citation: Pediatr Neurol. 1999 Oct;21(4):731-4
references.pmid: 10580886
references.citation: Cell Mol Life Sci. 2001 Jun;58(7):931-59
references.pmid: 11497241
references.citation: J Clin Psychiatry. 1999;60 Suppl 23:14-9
references.pmid: 10625195
references.citation: Int J Clin Pharmacol Ther. 2000 Feb;38(2):69-74
references.pmid: 10706193
references.citation: J Histochem Cytochem. 2005 Apr;53(4):517-31
references.pmid: 15805426
references.citation: Epilepsy Res. 2004 Feb;58(2-3):85-91
references.pmid: 15120740
references.citation: J Pharmacol Exp Ther. 2002 Apr;301(1):7-14
references.pmid: 11907151
references.citation: Neuroreport. 2001 Nov 16;12(16):3557-60
references.pmid: 11733711
references.citation: Pharmacogenomics. 2001 Feb;2(1):51-64
references.pmid: 11258197
references.citation: Curr Drug Metab. 2004 Feb;5(1):21-53
references.pmid: 14965249
references.citation: Epilepsia. 1995 Jan;36(1):1-6
references.pmid: 8001500
references.citation: Hepatology. 1998 Feb;27(2):537-45
references.pmid: 9462655
references.citation: Brain Res. 2000 Sep 8;876(1-2):148-53
references.pmid: 10973603
references.citation: Cell Mol Life Sci. 2004 Mar;61(6):682-99
references.pmid: 15052411
references.citation: Brain Res. 1999 Feb 20;819(1-2):143-6
references.pmid: 10082869
references.citation: J Neurosci Res. 2000 Jun 1;60(5):594-601
references.pmid: 10820430
references.citation: Biol Psychiatry. 2003 Oct 15;54(8):840-6
references.pmid: 14550684
references.citation: Nat Neurosci. 2001 Mar;4(3):268-74
references.pmid: 11224543
references.citation: Biochem Biophys Res Commun. 2001 Jun 22;284(4):863-9
references.pmid: 11409873
references.citation: Food Chem Toxicol. 2004 Jun;42(6):995-1002
references.pmid: 15110109
references.citation: J Pharmacol Exp Ther. 2003 Apr;305(1):197-204
references.pmid: 12649369
references.citation: Epilepsy Res. 2002 Oct;51(3):257-68
references.pmid: 12399076
references.citation: J Clin Invest. 2002 Nov;110(9):1309-18
references.pmid: 12417570
references.citation: Eur J Clin Invest. 2003 Nov;33 Suppl 2:6-9
references.pmid: 14641550
references.citation: Anaesth Intensive Care. 2002 Apr;30(2):183-91
references.pmid: 12002926
references.citation: J Natl Cancer Inst. 2000 Aug 16;92(16):1295-302
references.pmid: 10944550
references.citation: Epilepsia. 2001 Dec;42(12):1501-6
references.pmid: 11879359
references.citation: AIDS. 2001 Mar 9;15(4):483-91
references.pmid: 11242145
references.citation: Biochem J. 2003 Dec 1;376(Pt 2):313-38
references.pmid: 13678421
references.citation: Neuroreport. 2004 Jul 19;15(10):1657-61
references.pmid: 15232302
references.citation: Novartis Found Symp. 2002;243:83-96; discussion 96-102, 180-5
references.pmid: 11990784
references.citation: Drug Metab Dispos. 2000 Sep;28(9):1058-62
references.pmid: 10950849
references.citation: J Neurochem. 1997 Mar;68(3):1278-85
references.pmid: 9048775
references.citation: J Pharm Sci. 2003 Sep;92(9):1739-53
references.pmid: 12949994
references.citation: J Neurochem. 2002 Aug;82(3):716-9
references.pmid: 12153495
references.citation: Scand J Rheumatol. 2003;32(6):325-36
references.pmid: 15080263
references.citation: Cancer Treat Rev. 2000 Dec;26(6):449-62
references.pmid: 11139374
references.citation: Biochim Biophys Acta. 1976 Nov 11;455(1):152-62
references.pmid: 990323
references.citation: Ann Neurol. 2003 Apr;53(4):469-79
references.pmid: 12666114
references.citation: Psychoneuroendocrinology. 2004 May;29(4):423-47
references.pmid: 14749091
references.citation: Curr Pharm Des. 2004;10(12):1295-312
references.pmid: 15134482
references.citation: Epilepsy Res. 2004 Jan;58(1):67-79
references.pmid: 15066676
references.citation: Neuroscience. 2003;118(2):417-29
references.pmid: 12699778
references.citation: Neuroreport. 2001 Aug 8;12(11):2387-9
references.pmid: 11496115
references.citation: Epilepsy Res. 1999 Apr;34(2-3):109-22
references.pmid: 10210025
references.citation: Int J Neuropsychopharmacol. 2004 Sep;7(3):341-9
references.pmid: 15003146
references.citation: Pharm Res. 2000 Jun;17(6):749-53
references.pmid: 10955852
references.citation: Eur J Pharmacol. 2002 Sep 13;451(2):149-55
references.pmid: 12231384
references.citation: J Neurosci. 2002 Jul 15;22(14):5833-9
references.pmid: 12122045
references.citation: Neuroreport. 2003 Nov 14;14(16):2041-6
references.pmid: 14600494
references.citation: Adv Drug Deliv Rev. 2000 Dec 15;45(2-3):295-307
references.pmid: 11108981
references.citation: Cell Mol Neurobiol. 2000 Apr;20(2):165-81
references.pmid: 10696508
references.citation: Antimicrob Agents Chemother. 2002 Jul;46(7):2284-6
references.pmid: 12069991
references.citation: Drug Metab Dispos. 1999 Jul;27(7):827-34
references.pmid: 10383928
references.citation: Drug Metab Dispos. 1999 Aug;27(8):937-41
references.pmid: 10421622
references.citation: Brain Res. 2003 May 9;971(2):221-31
references.pmid: 12706238
references.citation: Exp Brain Res. 1999 Jun;126(4):509-16
references.pmid: 10422714
references.citation: J Drug Target. 2002 Feb;10(1):73-9
references.pmid: 11996089
references.citation: J Clin Invest. 2000 Feb;105(3):279-85
references.pmid: 10675353
references.citation: Lancet. 2001 Jan 6;357(9249):42-3
references.pmid: 11197364
references.citation: Adv Drug Deliv Rev. 2003 Jan 21;55(1):3-29
references.pmid: 12535572
references.citation: J Neurovirol. 1999 Dec;5(6):556-69
references.pmid: 10602397
references.citation: N Engl J Med. 2000 Feb 3;342(5):314-9
references.pmid: 10660394